-
1 week ago | 
medscape.com | Nancy A. Melville
SAN DIEGO — In treating pancreas divisum, the common use of endoscopic retrograde cholangiopancreatography (ERCP) with minor papilla endoscopic sphincterotomy showed no significant benefit over a sham procedure, suggesting that patients can be spared the intervention, which can carry risks of its own. “This is a topic that has been debated for decades,” said first author Gregory A.
-
1 week ago | 
medscape.com | Nancy A. Melville
In the treatment of non-Hodgkin lymphoma with CD19 chimeric antigen receptor (CAR) T-cell therapy, baseline kidney function did not appear to be associated with an increased risk of developing acute kidney injury (AKI) from the treatment. However, other key factors, including low albumin, showed a link.
-
1 week ago | 
medscape.com | Nancy A. Melville
SAN DIEGO — Patients with obesity and type 2 diabetes treated with glucagon-like peptide 1 (GLP-1) receptor agonists had significantly reduced rates for colorectal cancer (CRC) risk and associated mortality compared with those undergoing bariatric surgery, new research showed. CRC risk was also lower for patients taking GLP-1s than the general population.
-
1 week ago | 
medscape.com | Nancy A. Melville
SAN DIEGO — Molecular residual disease (MRD) positivity, as detected via circulating tumor (ct) DNA following curative resection, was significantly associated with improved disease-free survival after chemotherapy in patients with stage II or III colorectal cancer (CRC), the results of the BESPOKE study showed.
-
1 week ago | 
portugues.medscape.com | Nancy A. Melville
A presença de cinco proteínas-chave na circulação sanguínea está fortemente associada ao surgimento da esteatose hepática associada à disfunção metabólica (EHADM) até 16 anos antes do aparecimento de sinais e sintomas, segundo uma nova pesquisa. “Esse é o primeiro modelo preditivo ultraprecoce (com 16 anos [de antecedência]) e de alto desempenho para a EHADM”, disse a autora principal Dra.
-
1 week ago | 
medscape.com | Nancy A. Melville
SAN DIEGO — Patients with cirrhosis treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant reductions in a range of portal hypertension complications and all-cause mortality compared with those not receiving the drugs, new research shows. “Our study found that SGLT2 inhibitors were associated with fewer portal hypertension complications and lower mortality, suggesting they may be a valuable addition to cirrhosis management,” first author Abhinav K.
-
2 weeks ago | 
mdedge.com | Nancy A. Melville
FROM DDW 2025SAN DIEGO – The presence of five key proteins in the blood was strongly associated with the development of metabolic dysfunction-associated steatotic liver disease (MASLD) as much as 16 years before symptoms appeared, new research showed. “This represents the first high-performance, ultra-early (16 years) predictive model for MASLD,” said first author Shiyi Yu, MD, resident physician in the department of gastroenterology, Guangdong Provincial People’s Hospital in China.
-
2 weeks ago | 
medauth2.mdedge.com | Nancy A. Melville
Article Type Changed Tue, 04/29/2025 - 16:11 SAN DIEGO – Patients carrying at least one of the four key genes show a significantly increased risk for disease recurrence and mortality in gastric cancer, according to new research that potentially paves the way for precision oncology and improved targeting of therapies.
-
2 weeks ago | 
mdedge.com | Nancy A. Melville
FROM DDW 2025SAN DIEGO – Patients carrying at least one of the four key genes show a significantly increased risk for disease recurrence and mortality in gastric cancer, according to new research that potentially paves the way for precision oncology and improved targeting of therapies.
-
2 weeks ago | 
medscape.com | Nancy A. Melville
Patients carrying at least one of the four key genes show a significantly increased risk for disease recurrence and mortality in gastric cancer, according to new research that potentially paves the way for precision oncology and improved targeting of therapies.
